Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diffuse Large B Cell Lymphoma: early-phase trial registry
53 of 115 indexed Diffuse Large B Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #110 of 28,707 conditions by registered trial count.
115 US clinical trials · 53 currently recruiting · #110 of 28,707 conditions by registered trial count
Diffuse Large B Cell Lymphoma: 115 US clinical trials tracked, 53 recruiting.
Diffuse Large B Cell Lymphoma is the subject of 115 registered US clinical trials on ClinicalTrials.gov, 53 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 88 in Phase 1-2 (earlier-stage). The most active sponsor is Genmab, running 6 of these trials.
Enrollment posture brief
Registry condition diffuse-large-b-cell-lymphoma
OPEN 53 | RECR 46% | LATE 11 | EARLY 88 | RANK #110 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Recurrent Glioblastoma (46% recruiting · 63 trials)
Diffuse Large B Cell Lymphoma lists 53 open slots (46% of 115 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diffuse Large B Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diffuse Large B Cell Lymphoma is recruiting above its size-band peers.
53 of 115 indexed trials (46.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diffuse Large B Cell Lymphoma trials is spread across many organizations.
Genmab accounts for 6 of 115 trials (5.2%). 77 distinct sponsors appear on at least one study for this condition label.
-
Most Diffuse Large B Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 52 among the 115 trials that report a genuine target (sentinel values excluded). 72 of those (62.6%) plan for fewer than 100 participants.
-
Diffuse Large B Cell Lymphoma research is mostly interventional.
107 interventional and 8 observational studies make up this index (93% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
115 total, page 1 of 3
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
OWKIN
NCT06625203
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Merck Sharp & Dohme
NCT06717347
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Janssen Research & Development
NCT01804686
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
BeOne Medicines
NCT05006716
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Medical College of Wisconsin
NCT03375619
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
NCT05633615
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Genmab
NCT06508658
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
AstraZeneca
NCT04594642
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Adaptive Biotechnologies
NCT05255354
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Merck Sharp & Dohme
NCT05139017
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT04104776
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics
NCT02227251
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Emory University
NCT03501576
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine
NCT06022029
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Cancer Institute (NCI)
NCT03223610
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
AbbVie
NCT05512390
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
NCT05618028
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics
NCT05365659
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT04002947
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
NCT04186520
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Incyte Corporation
NCT04981795
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme
NCT06395103
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
AstraZeneca
NCT05952024
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical
NCT04775745
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.
NCT05660395
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Cancer Institute (NCI)
NCT04739813
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT06736613
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
OHSU Knight Cancer Institute
NCT06784167
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Hua-Jay J Cherng, MD
NCT06693830
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
NCT05618366
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Washington University School of Medicine
NCT06687772
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
NCT04545762
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
University of Washington
NCT05455697
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics
NCT06533579
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
NCT06863402
Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma
University of Texas Southwestern Medical Center
NCT06768905
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister
NCT05281809
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
OHSU Knight Cancer Institute
NCT06249191
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Marcela V. Maus, M.D.,Ph.D.
NCT06550141
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
H. Lee Moffitt Cancer Center and Research Institute
NCT05757219
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
New York Medical College
NCT02393157
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Marcela V. Maus, M.D.,Ph.D.
NCT06026319
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
NCT05256641
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Virginia Commonwealth University
NCT06846463
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Joshua Sasine, MD, PhD
NCT05887167
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Weill Medical College of Cornell University
NCT05934838
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Washington University School of Medicine
NCT05412290
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT05432635
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
NCT05990465
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04512716
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 58 |
| Phase 2 | 30 |
| Phase 3 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Diffuse Large B Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diffuse Large B Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diffuse Large B Cell Lymphoma page
115 registered trials, 53 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 53 Diffuse Large B Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Genmab sponsors the most Diffuse Large B Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Genmab's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diffuse Large B Cell Lymphoma condition card totals 115 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.